AZN
ASTRAZENECA PLC
NYSE: AZN · Cambridge · Healthcare
$195.78-4.91 (-2.45%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$130.19 – $208.62
Avg Volume2.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$195.78+44.9%
Pipeline

Drug candidates sponsored by ASTRAZENECA · ClinicalTrials.gov

91 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Esomeprazole
GERD
Completed
2002-10past
1
Phase 4quetiapine fumarate
Schizophrenia+2 more
Completed
2008-10past
2
Phase 4Quetiapine Fumarate XR
Schizophrenia
Completed
2009-07past
1
Phase 4Ticagrelor
Stable Coronary Artery Disease
Completed
2013-09past
1
Phase 4Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Non ST-elevation Myocardial Infarction
Completed
2017-02-09past
1
Phase 4Sodium Zirconium Cyclosilicate (SZC)
Hyperkalaemia+1 more
Completed
2024-12-10past
1
Phase 4Dexamethasone mouthwash
Stomatitis
Not yet recruiting
2027-10-09
1
Phase 3Seroquel SR
Schizophrenia
Completed
2006-02past
1
Phase 3Ciclesonide nasal spray
Hay Fever+1 more
Completed
2006-10past
1
Phase 3Ciclesonide
Rhinitis, Allergic, Perennial+1 more
Completed
2006-11past
2
Phase 3Saxagliptin
Diabetes
Completed
2007-09past
1
Phase 3Roflumilast
Chronic Obstructive Pulmonary Disease (COPD)+1 more
Completed
2007-11past
2
Phase 3Dapagliflozin
Type 2 Diabetes
Completed
2010-01past
1
Phase 3Aclidinium Bromide
Chronic Obstructive Pulmonary Disease (COPD)
Completed
2012-06past
1
Phase 375mg selumetinib
Metastatic+1 more
Completed
2015-05past
1
Phase 3Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
Chronic Obstructive Pulmonary Disease
Completed
2017-06-08past
1
Phase 3Benralizumab Arm A
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Completed
2018-04-10past
1
Phase 3Anifrolumab
Active Systemic Lupus Erythematosus
Completed
2018-09-27past
1
Phase 3placebo
Type 2 Diabetes+1 more
Completed
2020-07-08past
3
Phase 3Durvalumab
Locally Advanced Cervical Cancer
Completed
2022-01-20past
1
Phase 3Aclidinium bromide/formoterol Fixed-Dose Combination
COPD
Completed
2022-04-14past
1
Phase 3Monalizumab
Squamous Cell Carcinoma of the Head and Neck
Active, not recruiting
2022-05-11past
1
Phase 3Dato-DXd
Breast Cancer
Recruiting
2027-07-28
1
Phase 3Unnamed
Asthma
Recruiting
2027-10-13
1
Phase 3Benralizumab
Eosinophilic Granulomatosis With Polyangiitis (EGPA)+3 more
Recruiting
2028-02-21
2
Phase 3Budesonide/formoterol pMDI
Chronic Obstructive Pulmonary Disease
Completed—1
Phase 3Budesonide/formoterol Turbuhaler
Asthma
Completed—1
Phase 3Anastrozole
Breast Cancer+2 more
Completed—3
Phase 2ZD6126
Colorectal Neoplasms+1 more
Terminated
2004-02past
1
Phase 2budesonide
Exercise Induced Asthma
Completed
2010-07past
1
Phase 2AZD2516, 5 mg
Reflux
Completed
2010-09past
1
Phase 2Fostamatinib
Rheumatoid Arthritis
Terminated
2013-07past
1
Phase 2Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
Pulmonary Disease, Chronic Obstructive
Completed
2018-06-12past
1
Phase 2Acalabrutinib
COVID-19
Completed
2020-11-16past
1
Phase 2Trastuzumab deruxtecan
HER2-mutant Non-Small Cell Lung Cancer
Active, not recruiting
2023-09-23past
1
Phase 2Brazikumab
Ulcerative Colitis+1 more
Terminated
2023-10-23past
1
Phase 1AZD3632
Acute Lymphoblastic Leukaemia+2 more
Recruiting
2029-02-15
1
Phase 1AZD6621
Prostate Cancer
Recruiting
2029-03-29
1
Phase 2Tomudex
Inoperable or Recurrent Rectal Cancer
Completed—1
Phase 1Gefitinib, radiotherapy
Non-Metastatic Prostate Cancer
Completed—1
Phase 2IR (Immediate-Release) quetiapine fumarate (drug)
Schizophrenia
Completed—1
Phase 1CP-675,206
Melanoma
Completed
2008-02past
1
Phase 1AZD3355
Gastroesophageal Reflux Disease
Completed
2008-06past
1
Phase 1AZD6140
Gout+1 more
Completed
2008-07past
1
Phase 1AZD7325
Healthy Volunteer
Completed
2008-09past
1
Phase 1monophasic oral contraceptive
Pharmacokinetics
Suspended
2009-09past
1
Phase 1AZD2171
Carcinoma, Non-Small-Cell Lung+2 more
Completed
2010-07past
2
Phase 1AZD1981
Oral Contraceptives
Completed
2010-10past
1
Phase 1AZD8848
Healthy Volunteers
Completed
2011-03past
1
Phase 1D961H Sachet 20 mg
Bioequivalence Study
Completed
2012-06past
1
Phase 1Pramlintide acetate
Type 1 Diabetes
Completed
2013-09past
1
Phase 1Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Bioequivalence+2 more
Completed
2015-08past
1
Phase 1Lanabecestat
Healthy
Completed
2016-01-31past
1
Phase 1Fexofenadine tablet dosing
Non Small Cell Lung Cancer
Completed
2017-07-31past
1
Phase 1AZD5718 tablet, Formulation A
Coronary Artery Disease (CAD)
Completed
2020-03-09past
1
Phase 1AZD7594
Asthma
Completed
2020-07-09past
1
Phase 1AZD3427
Heart Failure
Withdrawn
2022-08-02past
1
Phase 1AZD0466
Non-Hodgkin Lymphoma
Terminated
2023-08-17past
1
Phase 1AZD9838
COVID-19+1 more
Completed
2024-04-30past
1
Phase 1Treatment A: BGF MDI HFA
Chronic Obstructive Pulmonary Disease
Completed
2024-06-11past
1
Phase 1Saruparib
Advanced Solid Malignancies
Active, not recruiting
2026-02-03past
1
Phase 1AZD1043
Healthy Participants+1 more
Recruiting
2027-03-15
1
Phase 1AZD7268
Healthy
Completed—1
Phase 1AZD2066
Pain
Completed—1
Phase 1AZD0837
Healthy
Completed—1
N/AUnnamed
Schizophrenia+4 more
Terminated
2008-12past
1
N/AUnnamed
Cardiovascular Risk
Completed
2010-01past
1
N/AUnnamed
Advanced Prostate Cancer
Completed
2010-01past
1
N/AUnnamed
Schizophrenia
Completed
2010-03past
1
N/AUnnamed
Non Small Cell Lung Cancer
Completed
2010-08past
1
N/AUnnamed
Gastroesophageal Reflux Disease
Completed
2010-11past
1
N/AAZD2423
Neuroscience
Completed
2010-12past
1
N/AUnnamed
Dyslipidemia+1 more
Completed
2011-12past
1
N/AUnnamed
Chronic Obstructive Pulmonary Disease
Completed
2012-10past
1
N/AUnnamed
ACS+4 more
Completed
2013-03past
1
N/AUnnamed
Uncomplicated Peptic Ulcer
Completed
2013-05past
1
N/AUnnamed
EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Completed
2014-04past
1
N/AUnnamed
Patients With Asthma-COPD Overlap Syndrome (ACOS)
Completed
2017-04-28past
1
N/AUnnamed
Acute Coronary Syndrome
Completed
2017-06-24past
1
N/AUnnamed
Ovarian Cancer
Completed
2018-07-06past
1
N/AUnnamed
Adult Patients With Type 2 Diabetes Mellitus
Completed
2019-08-30past
1
N/AUnnamed
Ovarian Cancer
Terminated
2020-03-31past
1
N/AUnnamed
Heart Failure
Completed
2024-03-02past
1
N/AUnnamed
Heart Failure
Completed
2024-08-22past
1
N/AUnnamed
Major Bleeding
Completed
2024-11-30past
1
N/AUnnamed
Chronic Obstructive Pulmonary Disease
Withdrawn
2025-12-31past
1
N/APalivizumab 15 mg/kg
Respiratory Syncytial Virus (RSV)
Recruiting
2027-02-28
1
N/AUnnamed
Lysosomal Acid Lipase Deficiency
Recruiting
2028-06-30
1
N/AUnnamed
Ovarian Cancer
Recruiting
2033-03-31
1
N/AUnnamed
Hyperlipidemia
Completed—1
N/ASymbicort
Perception of Physicians & Patients of AMD
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for AZN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.